These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33068780)

  • 1. Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019).
    Shortridge D; Pfaller MA; Streit JM; Flamm RK
    J Glob Antimicrob Resist; 2020 Dec; 23():278-283. PubMed ID: 33068780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: Results from the SENTRY Antimicrobial Surveillance Programme, 2017.
    Huband MD; Pfaller MA; Shortridge D; Flamm RK
    J Glob Antimicrob Resist; 2019 Dec; 19():56-63. PubMed ID: 30825698
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delafloxacin
    Pfaller MA; Flamm RK; McCurdy SP; Pillar CM; Shortridge D; Jones RN
    J Clin Microbiol; 2018 Aug; 56(8):. PubMed ID: 29848564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delafloxacin activity against Staphylococcus aureus with reduced susceptibility or resistance to methicillin, vancomycin, daptomycin or linezolid.
    Saravolatz LD; Pawlak JM; Wegner C
    J Antimicrob Chemother; 2020 Sep; 75(9):2605-2608. PubMed ID: 32542310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial.
    McCurdy S; Keedy K; Lawrence L; Nenninger A; Sheets A; Quintas M; Cammarata S
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of Omadacycline Activity Tested against Clinical Isolates from the United States and Europe: Report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018.
    Pfaller MA; Huband MD; Shortridge D; Flamm RK
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071045
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pfaller MA; Sader HS; Rhomberg PR; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America.
    Sader HS; Streit JM; Carvalhaes CG; Huband MD; Pfaller MA
    J Glob Antimicrob Resist; 2019 Jun; 17():103-108. PubMed ID: 30458298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study.
    O'Riordan W; McManus A; Teras J; Poromanski I; Cruz-Saldariagga M; Quintas M; Lawrence L; Liang S; Cammarata S;
    Clin Infect Dis; 2018 Aug; 67(5):657-666. PubMed ID: 29518178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of JNJ-Q2 activity tested against Staphylococcus aureus and beta-hemolytic streptococci as a component of the 2010 SENTRY Antimicrobial Surveillance Program.
    Farrell DJ; Liverman LC; Biedenbach DJ; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2011 Dec; 71(4):415-20. PubMed ID: 21982563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18.
    Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Dhole T; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Joshi P; Khande H; Mane A; Jain R; Bhagwat S
    J Antimicrob Chemother; 2020 Mar; 75(3):600-608. PubMed ID: 31840170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.
    Scott LJ
    Drugs; 2020 Aug; 80(12):1247-1258. PubMed ID: 32666425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa.
    Ocheretyaner ER; Park TE
    Expert Rev Anti Infect Ther; 2018 Jul; 16(7):523-530. PubMed ID: 29911455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.
    Righi E; Carnelutti A; Vena A; Bassetti M
    Infect Drug Resist; 2018; 11():479-488. PubMed ID: 29670380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018.
    Flamm RK; Duncan LR; Hamed KA; Smart JI; Mendes RE; Pfaller MA
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32179519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: redefining the baseline activity of telavancin.
    Mendes RE; Flamm RK; Farrell DJ; Sader HS; Jones RN
    J Chemother; 2016 Apr; 28(2):83-8. PubMed ID: 26058844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delafloxacin--A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis.
    Millar BC; McCaughan J; Rendall JC; Moore JE
    Clin Respir J; 2021 Jan; 15(1):116-120. PubMed ID: 32790958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
    Kaul G; Kapoor E; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Nov; 54(11):657-666. PubMed ID: 30539165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.